• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心力衰竭生物标志物的血浆水平主要反映的是心脏外的产生情况。

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production.

机构信息

Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.

Department of Pharmacology (State-Province Key Laboratories of Biomedicine- Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China.

出版信息

Theranostics. 2018 Jul 30;8(15):4155-4169. doi: 10.7150/thno.26055. eCollection 2018.

DOI:10.7150/thno.26055
PMID:30128044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6096401/
Abstract

Plasma heart failure (HF) biomarkers, like natriuretic peptides, are important in diagnosis, prognosis and HF treatment. Several novel HF biomarkers have been identified, including Gal-3, GDF-15 and TIMP-1, but their clinical potential remains vague. Here we investigated plasma biomarker levels in relation to tissue expression and structural and functional cardiac changes. Cardiac remodeling, cardiac function, and plasma and tissue biomarker levels were investigated in mice after myocardial infarction induced by temporal and permanent LAD ligation (tLAD and pLAD). In addition, a pressure overload model induced by transverse aortic constriction (TAC) and an obese/hypertensive HFpEF-like mouse model were investigated. Plasma levels of ANP and its cardiac expression were strictly associated with cardiac remodeling and function. Gal-3, GDF-15 and TIMP-1 cardiac expressions were also related to cardiac remodeling and function, but not their plasma levels. Only directly after myocardial infarction could elevated plasma levels of Gal-3 and TIMP-1 be detected. Eight weeks after infarction, plasma levels were not elevated despite enhanced cardiac expression and low EF (18.3±3.3%, pLAD). Plasma levels of TIMP-1 and GDF-15 were elevated after TAC, but this also correlated with increased lung expression and congestion. In obese-hypertensive mice, elevated plasma levels of Gal-3, GDF-15 and TIMP1 were associated with increased adipose tissue expression and not with cardiac function. The Gal-3, GDF-15 and TIMP-1 plasma pool levels are hardly influenced by dynamic changes in cardiac expression. These biomarkers are not specific for indices of cardiac remodeling, but predominantly reflect stress in other affected tissues and hence provide health information beyond the heart.

摘要

血浆心力衰竭(HF)生物标志物,如利钠肽,在诊断、预后和 HF 治疗中很重要。已经鉴定出几种新型 HF 生物标志物,包括 Gal-3、GDF-15 和 TIMP-1,但它们的临床潜力仍不明确。在这里,我们研究了与组织表达以及心脏结构和功能变化相关的血浆生物标志物水平。

通过暂时和永久性 LAD 结扎(tLAD 和 pLAD)诱导心肌梗死后,我们研究了小鼠的心脏重塑、心脏功能以及血浆和组织生物标志物水平。此外,还研究了通过横主动脉缩窄(TAC)诱导的压力超负荷模型和肥胖/高血压 HFpEF 样小鼠模型。

ANP 的血浆水平及其心脏表达与心脏重塑和功能密切相关。Gal-3、GDF-15 和 TIMP-1 的心脏表达也与心脏重塑和功能有关,但与它们的血浆水平无关。只有在心肌梗死后才能检测到升高的 Gal-3 和 TIMP-1 血浆水平。梗塞 8 周后,尽管 EF 降低(18.3±3.3%,pLAD),但心脏表达增强,血浆水平并未升高。TAC 后 TIMP-1 和 GDF-15 的血浆水平升高,但这也与肺表达增加和充血有关。在肥胖高血压小鼠中,Gal-3、GDF-15 和 TIMP1 的血浆水平升高与脂肪组织表达增加有关,而与心脏功能无关。

Gal-3、GDF-15 和 TIMP-1 的血浆池水平几乎不受心脏表达动态变化的影响。这些生物标志物不是心脏重塑指数的特异性标志物,主要反映其他受影响组织的应激情况,因此提供了超越心脏的健康信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/e8b2a7d00f00/thnov08p4155g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/ff07b876bb98/thnov08p4155g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/6b2d71bd299b/thnov08p4155g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/b2f12811269f/thnov08p4155g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/2418aefd574f/thnov08p4155g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/039ca322b64f/thnov08p4155g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/f45d22c4c481/thnov08p4155g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/e8b2a7d00f00/thnov08p4155g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/ff07b876bb98/thnov08p4155g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/6b2d71bd299b/thnov08p4155g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/b2f12811269f/thnov08p4155g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/2418aefd574f/thnov08p4155g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/039ca322b64f/thnov08p4155g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/f45d22c4c481/thnov08p4155g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b8/6096401/e8b2a7d00f00/thnov08p4155g007.jpg

相似文献

1
Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production.心力衰竭生物标志物的血浆水平主要反映的是心脏外的产生情况。
Theranostics. 2018 Jul 30;8(15):4155-4169. doi: 10.7150/thno.26055. eCollection 2018.
2
The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.生长分化因子 15、半乳糖凝集素 3 和可溶性 ST2 作为心力衰竭保留射血分数和心力衰竭射血分数降低的诊断生物标志物的效用:系统评价。
Heart Fail Rev. 2021 Jul;26(4):799-812. doi: 10.1007/s10741-020-09913-3.
3
Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.可溶性 ST2、半乳糖凝集素-3 和生长分化因子-15 与心力衰竭和其他非心脏疾病的关系。
Clin Chim Acta. 2015 May 20;445:155-60. doi: 10.1016/j.cca.2015.03.033. Epub 2015 Apr 4.
4
Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction.血浆 tenascin-C:射血分数保留的心力衰竭的预后生物标志物。
Biomarkers. 2020 Nov;25(7):556-565. doi: 10.1080/1354750X.2020.1810319. Epub 2020 Aug 28.
5
Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.中段肾上腺髓质素和生长分化因子-15不受心力衰竭患者肥胖的影响。
Clin Res Cardiol. 2017 Jun;106(6):401-410. doi: 10.1007/s00392-016-1066-x. Epub 2016 Dec 21.
6
Novel heart failure biomarkers: why do we fail to exploit their potential?新型心力衰竭生物标志物:为何未能挖掘其潜力?
Crit Rev Clin Lab Sci. 2018 Jun;55(4):246-263. doi: 10.1080/10408363.2018.1460576. Epub 2018 Apr 17.
7
Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.用于心力衰竭特征描述的生物标志物——射血分数保留型与射血分数降低型心力衰竭的鉴别
Int J Cardiol. 2017 Jan 15;227:272-277. doi: 10.1016/j.ijcard.2016.11.110. Epub 2016 Nov 9.
8
[Plasma concentration of growth-differentiation factor-15 in children with congenital heart disease: relation ship to heart function and diagnostic value in heart failure].先天性心脏病患儿血浆生长分化因子-15浓度:与心功能的关系及在心力衰竭中的诊断价值
Zhongguo Dang Dai Er Ke Za Zhi. 2013 Feb;15(2):95-8.
9
Variability of biomarkers in patients with chronic heart failure and healthy controls.慢性心力衰竭患者与健康对照者生物标志物的变异性。
Eur J Heart Fail. 2017 Mar;19(3):357-365. doi: 10.1002/ejhf.669. Epub 2016 Oct 21.
10
Biomarkers and diagnostics in heart failure.心力衰竭中的生物标志物与诊断方法
Biochim Biophys Acta. 2013 Dec;1832(12):2442-50. doi: 10.1016/j.bbadis.2012.12.014. Epub 2013 Jan 9.

引用本文的文献

1
The senescence-inducing factor IGFBP7 and risk of atrial fibrillation: findings from the PREVEND study.衰老诱导因子IGFBP7与心房颤动风险:PREVEND研究的结果
NPJ Cardiovasc Health. 2025;2(1):42. doi: 10.1038/s44325-025-00079-1. Epub 2025 Aug 12.
2
Investigation of Growth Differentiation Factor 15 as a Prognostic Biomarker for Major Adverse Limb Events in Peripheral Artery Disease.生长分化因子15作为外周动脉疾病主要肢体不良事件预后生物标志物的研究
J Clin Med. 2025 Jul 24;14(15):5239. doi: 10.3390/jcm14155239.
3
Growth Differentiation Factor 15 Predicts Cardiovascular Events in Peripheral Artery Disease.

本文引用的文献

1
Novel heart failure biomarkers: why do we fail to exploit their potential?新型心力衰竭生物标志物:为何未能挖掘其潜力?
Crit Rev Clin Lab Sci. 2018 Jun;55(4):246-263. doi: 10.1080/10408363.2018.1460576. Epub 2018 Apr 17.
2
Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.半乳糖凝集素-3 在心力衰竭和心血管疾病中的激活与抑制:最新进展。
Theranostics. 2018 Jan 1;8(3):593-609. doi: 10.7150/thno.22196. eCollection 2018.
3
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
生长分化因子15预测外周动脉疾病中的心血管事件。
Biomolecules. 2025 Jul 11;15(7):991. doi: 10.3390/biom15070991.
4
A predictive model for heart failure with preserved ejection fraction following acute myocardial infarction: the HFpEF-AMI score.急性心肌梗死后射血分数保留的心力衰竭预测模型:HFpEF-AMI评分
BMC Cardiovasc Disord. 2025 Jul 23;25(1):535. doi: 10.1186/s12872-025-04969-1.
5
Increased Plasma Pyruvate Kinase M2 (PK-M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications.心力衰竭患者血浆丙酮酸激酶M2(PK-M2)升高:一种与心功能相关的新型生物标志物及其临床意义
J Am Heart Assoc. 2025 Jan 21;14(2):e036170. doi: 10.1161/JAHA.124.036170. Epub 2025 Jan 16.
6
Transcoronary study of biomarkers in patients with heart failure: Insights into intracardiac production.心力衰竭患者生物标志物的经冠状动脉研究:对心内生成的见解
ESC Heart Fail. 2025 Jun;12(3):1640-1651. doi: 10.1002/ehf2.15175. Epub 2024 Dec 27.
7
Pathophysiology of Congestion in Heart Failure: A Contemporary Review.心力衰竭中充血的病理生理学:当代综述
Card Fail Rev. 2024 Sep 25;10:e13. doi: 10.15420/cfr.2024.07. eCollection 2024.
8
Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.心力衰竭筛查:在普通人群中检测风险升高的生物标志物。
Curr Heart Fail Rep. 2024 Dec;21(6):591-603. doi: 10.1007/s11897-024-00686-6. Epub 2024 Sep 17.
9
Heart Failure: Is There an Ideal Biomarker?心力衰竭:是否存在理想的生物标志物?
Rev Cardiovasc Med. 2023 Nov 9;24(11):310. doi: 10.31083/j.rcm2411310. eCollection 2023 Nov.
10
Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases.生长分化因子-15,一种氧化应激、炎症和细胞衰老的新型全身生物标志物:在心血管疾病中的潜在作用。
Am Heart J Plus. 2021 Aug 28;9:100046. doi: 10.1016/j.ahjo.2021.100046. eCollection 2021 Sep.
2017年美国心脏病学会/美国心脏协会/美国心力衰竭学会对2013年美国心脏病学基金会/美国心脏协会心力衰竭管理指南的重点更新:美国心脏病学会/美国心脏协会临床实践指南工作组及美国心力衰竭学会的报告
J Card Fail. 2017 Aug;23(8):628-651. doi: 10.1016/j.cardfail.2017.04.014. Epub 2017 Apr 28.
4
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.生物标志物在心衰的预防、评估和管理中的作用:美国心脏协会的科学声明。
Circulation. 2017 May 30;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26.
5
Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.心力衰竭患者保留和降低射血分数的生物标志物特征。
J Am Heart Assoc. 2017 Mar 30;6(4):e003989. doi: 10.1161/JAHA.116.003989.
6
Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.心力衰竭患者血浆和心脏半乳糖凝集素-3反映炎症和纤维化:其作为生物标志物的意义
Circ Heart Fail. 2017 Mar;10(3). doi: 10.1161/CIRCHEARTFAILURE.116.003804.
7
Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease.生长分化因子15作为心血管疾病的生物标志物
Clin Chem. 2017 Jan;63(1):140-151. doi: 10.1373/clinchem.2016.255174. Epub 2016 Oct 25.
8
Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance.造血来源的半乳糖凝集素-3导致细胞和全身性胰岛素抵抗。
Cell. 2016 Nov 3;167(4):973-984.e12. doi: 10.1016/j.cell.2016.10.025.
9
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.生长分化因子15预测稳定型冠心病的全因发病和死亡情况。
Clin Chem. 2017 Jan;63(1):325-333. doi: 10.1373/clinchem.2016.260570. Epub 2016 Nov 3.
10
Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review.射血分数保留的心力衰竭中生物标志物的临床应用:综述
Cardiology. 2017;136(3):192-203. doi: 10.1159/000450573. Epub 2016 Oct 27.